ZOBRIUS PHARMA ASA

3044 DRAMMEN

Finances

Share Ownership

Return on Equity

−199,28 %

Current Ratio

4,01

Debt-to-Equity Ratio

0,9

Key figures (NOK)	2022	2021	2020	2019
Revenue	128 000	37 000	2 264 000	57 000
Net Income	−3 336 000	−6 673 000	−2 868 000	−2 751 000
Total Assets	3 902 000	5 504 000	6 616 000	3 435 000
Total Equity	1 674 000	2 791 000	3 447 000	1 415 000

Income (NOK)	2022	2021	2020	2019
Revenue	128 000	37 000	2 264 000	57 000
Expenditure	3 303 000	7 306 000	5 031 000	4 731 000
Operating Profit	−3 258 000	−6 669 000	−2 767 000	−2 831 000
Financial Income	4 000	10 000	68 000	7 000
Financial Costs	82 000	14 000	168 000	21 000
Financial Balance	−78 000	−4 000	−100 000	−14 000
Earnings Before Tax	−3 336 000	−6 673 000	−2 868 000	−2 845 000
Tax	0	0	0	−94 000
Net Income	−3 336 000	−6 673 000	−2 868 000	−2 751 000

Balance (NOK)	2022	2021	2020	2019
Total Fixed Assets	984 000	349 000	50 000	156 000
Total Current Assets	2 918 000	5 155 000	6 566 000	3 279 000
Total Assets	3 902 000	5 504 000	6 616 000	3 435 000
Total Retained Equity	−16 887 000	−13 551 000	−6 878 000	−4 010 000
Total Equity	1 674 000	2 791 000	3 447 000	1 415 000
Total Long-Term Debt	1 500 000	1 500 000	1 500 000	1 500 000
Total Current Debt	728 000	1 213 000	1 669 000	520 000
Total Equity and Debt	3 902 000	5 504 000	6 616 000	3 435 000

Cash flow (NOK)	2022	2021	2020	2019
Sales Income	128 000	37 000	1 386 000	57 000
Other Income	0	0	879 000	0
Revenue	128 000	37 000	2 264 000	57 000
Cost of Goods Sold	289 000	719 000	1 612 000	1 872 000
Salary Costs	365 000	809 000	0	0
Depreciation	24 000	7 000	106 000	0
Impairment	0	0	0	0
Expenditure	3 303 000	7 306 000	5 031 000	4 731 000
Operating Profit	−3 258 000	−6 669 000	−2 767 000	−2 831 000
Financial Income	4 000	10 000	68 000	7 000
Financial Costs	82 000	14 000	168 000	21 000
Financial Balance	−78 000	−4 000	−100 000	−14 000
Dividends	0	0	0	0
Net Income	−3 336 000	−6 673 000	−2 868 000	−2 751 000

Balance details (NOK)	2022	2021	2020	2019
Goodwill	0	0	0	0
Total Intangible Assets	868 000	216 000	0	106 000
Real Eastate	0	0	0	0
Machinery and Plant Facilities	0	0	0	0
Fixtures	63 000	81 000	0	0
Total Tangible Assets	63 000	81 000	0	0
Total Fiancial Fixed Assets	53 000	52 000	50 000	50 000
Total Fixed Assets	984 000	349 000	50 000	156 000
Stock	2 264 000	2 444 000	1 842 000	1 843 000
Total Investments	0	0	0	0
Cash, Bank	587 000	1 853 000	3 683 000	964 000
Total Current Assets	2 918 000	5 155 000	6 566 000	3 279 000
Total Assets	3 902 000	5 504 000	6 616 000	3 435 000
Total Equity	1 674 000	2 791 000	3 447 000	1 415 000
Short-Term Group Debt	0	0	0	0
Total Long-Term Debt	1 500 000	1 500 000	1 500 000	1 500 000
Creditors	454 000	962 000	1 054 000	81 000
Unpaid Taxes	29 000	181 000	0	0
Dividends	0	0	0	0
Other Current Debt	245 000	70 000	615 000	439 000
Total Current Debt	728 000	1 213 000	1 669 000	520 000
Total Equity and Debt	3 902 000	5 504 000	6 616 000	3 435 000

Financial indicators	2022	2021	2020	2019
Return on Equity	−199,28 %	−239,09 %	−83,2 %	−194,42 %
Debt-to-Equity Ratio	0,9	0,54	0,44	1,06
Operating Profit Margin	−2 545,31 %	−18 024,32 %	−122,22 %	−4 966,67 %
Current Ratio	4,01	4,25	3,93	6,31
Quick Ratio	−1,9	−4,19	−37,95	−2,48
Equity Ratio	0,43	0,51	0,52	0,41
Gross Profit Margin	−125,78 %	−1 843,24 %	28,8 %	−3 184,21 %